在表皮生长因子受体中药物耐药性的共同进化格局:癌症的视角
Gyan Prakash Rai1, Asheesh Shanker1
1Department of Bioinformatics, Central University of South Bihar, Gaya, Bihar, 824236, India.
非小细胞肺癌 (NSCLC) 的耐药性源于EGFR的进化. 补偿性改变扩大了药物结合口袋,降低了氨酸激酶抑制剂 (TKI) 的有效性,并需要新的药物设计.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 表皮生长因子受体 (EGFR) 在非小细胞肺癌 (NSCLC) 的进展中至关重要.
- 氨酸激酶抑制剂 (TKI) 是有效的,但由于EGFR变化而面临耐药性.
研究的目的:
- 为了研究EGFR驱动耐药性的补偿性变化.
- 了解NSCLC中TKI耐药性背后的进化机制.
主要方法:
- 分子动力学模拟.分子动力学模拟.
- 使用RMSD,RMSF,SASA,PCA和FEL进行结构变化的分析.
- MM-GBSA 的结合亲和度计算.
主要成果:
- 在EGFR的共同进化变化扩大了药物结合口袋,降低了TKI的疗效.
- 野生类型的EGFR结构与gefitinib比双重突变更稳定.
- 结构性调整显著影响了EGFR对药物的反应.
结论:
- 进化引起的EGFR结构变化有助于药物耐药性.
- 了解这些进化过程可以指导开发更有效的EGFR向疗法.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Treatment Resistant Cancers
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Epistasis
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
